---
figid: PMC3526371__nihms-424389-f0001
figtitle: NFKB activation in pathogenesis and therapy of cancer
organisms:
- Homo sapiens
- Mus musculus
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC3526371
filename: nihms-424389-f0001.jpg
figlink: /pmc/articles/PMC3526371/figure/F1/
number: F1
caption: 'NF-κB activation in pathogenesis and therapy of cancer. A. Canonical NF-κB
  activation is inducible by chronic exposure to bacteria, certain viral products,
  chemical promoters, carcinogens, cytotoxic agents and reactive oxygen species (ROS).
  Repeated DNA damage may result in constitutive activation of oncogenes upstream
  of the IKK complex, including EGFR, Her2, and KRAS. Intermediate kinases convey
  signals to the Inhibitor-κB complex formed by IKKα, β and γ, and IKKβ and CK2 phosphorylate
  Inhibitor-κB, marking it for ubiquitination and proteasome degradation. P105/RELA
  or cREL is processed to NF-κB1 (p50)/RELA or cREL heterodimers, which translocate
  to the nucleus and bind promoters of genes regulating proliferation, apoptosis,
  migration inflammation, angiogenesis, and innate immunity. B. Inactivation of tumor
  suppressor p53 enhances NF-κB activation. C. Non-canonical Pathway. The alternative
  pathway may be activated by other TNF family members via NIK, and involves IKKα/IKKα
  homodimers, which activate NF-κB2/p100 for processing into p52/RelB heterodimers.
  The Rel-B/p52 heterodimer then translocates into the nucleus to bind the promoters
  of genes whose products are important for the malignant phenotype in some cancers
  and B cell development and adaptive immunity. Red highlighted activators in adenocarcinoma
  include EGFR, Her2, KRAS; Inhibitors of NF-κB activation under clinical investigation
  include proteasome and IKK antagonists. Abbreviations: NF-κB, nuclear factor κB;
  IKK, Inhibitor-κB kinase; NIK, NF-κB inducing kinase; TNFR, Tumor Necrosis Factor
  Receptor; IL-1R, Interleukin 1 R; EGFR, Epidermal Growth Factor Receptor; TRAF,
  TNF receptor associated factor; TAK, transforming growth factor-beta activated kinase;
  FAK, Focal Adhesion Kinase; CK2, casein kinase 2; PI3-K, phosphatidylinositol 3-kinase;
  PDK, 3-phosphoinisitide dependent protein kinase'
papertitle: Targeting Nuclear Factor-κB in mouse models of lung adenocarcinoma.
reftext: Carter Van Waes. Cancer Discov. 2011 Aug;1(3):200-202.
year: '2011'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9502208
figid_alias: PMC3526371__F1
figtype: Figure
redirect_from: /figures/PMC3526371__F1
ndex: 003955a0-def6-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3526371__nihms-424389-f0001.html
  '@type': Dataset
  description: 'NF-κB activation in pathogenesis and therapy of cancer. A. Canonical
    NF-κB activation is inducible by chronic exposure to bacteria, certain viral products,
    chemical promoters, carcinogens, cytotoxic agents and reactive oxygen species
    (ROS). Repeated DNA damage may result in constitutive activation of oncogenes
    upstream of the IKK complex, including EGFR, Her2, and KRAS. Intermediate kinases
    convey signals to the Inhibitor-κB complex formed by IKKα, β and γ, and IKKβ and
    CK2 phosphorylate Inhibitor-κB, marking it for ubiquitination and proteasome degradation.
    P105/RELA or cREL is processed to NF-κB1 (p50)/RELA or cREL heterodimers, which
    translocate to the nucleus and bind promoters of genes regulating proliferation,
    apoptosis, migration inflammation, angiogenesis, and innate immunity. B. Inactivation
    of tumor suppressor p53 enhances NF-κB activation. C. Non-canonical Pathway. The
    alternative pathway may be activated by other TNF family members via NIK, and
    involves IKKα/IKKα homodimers, which activate NF-κB2/p100 for processing into
    p52/RelB heterodimers. The Rel-B/p52 heterodimer then translocates into the nucleus
    to bind the promoters of genes whose products are important for the malignant
    phenotype in some cancers and B cell development and adaptive immunity. Red highlighted
    activators in adenocarcinoma include EGFR, Her2, KRAS; Inhibitors of NF-κB activation
    under clinical investigation include proteasome and IKK antagonists. Abbreviations:
    NF-κB, nuclear factor κB; IKK, Inhibitor-κB kinase; NIK, NF-κB inducing kinase;
    TNFR, Tumor Necrosis Factor Receptor; IL-1R, Interleukin 1 R; EGFR, Epidermal
    Growth Factor Receptor; TRAF, TNF receptor associated factor; TAK, transforming
    growth factor-beta activated kinase; FAK, Focal Adhesion Kinase; CK2, casein kinase
    2; PI3-K, phosphatidylinositol 3-kinase; PDK, 3-phosphoinisitide dependent protein
    kinase'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - Erbb2
  - Ltb
  - Cd40lg
  - Tol1
  - Ptk2
  - Kras
  - Tnfrsf1a
  - Myd88
  - Traf6
  - Pik3r1
  - Traf2
  - Csnk2a1
  - Csnk2a2
  - Pdk1
  - Pdpk1
  - Map4k4
  - Map3k14
  - Nr2c2
  - Map3k7
  - Akt1
  - Pten
  - Nfkbib
  - Tpx2
  - Nedd9
  - Nfkb1
  - Scyl1
  - Relb
  - Rela
  - Rel
  - Nfkb2
  - Trp53
  - EGFR
  - ERBB2
  - ITGA1
  - ITGA10
  - ITGA11
  - ITGA2
  - ITGA2B
  - ITGA3
  - ITGA4
  - ITGA5
  - ITGA6
  - ITGA7
  - ITGA8
  - ITGA9
  - ITGAD
  - ITGAE
  - ITGAL
  - ITGAM
  - ITGAV
  - ITGAX
  - ITGB1
  - ITGB2
  - ITGB3
  - ITGB4
  - ITGB5
  - ITGB6
  - ITGB7
  - ITGB8
  - ITGBL1
  - IL1R1
  - LTB
  - CD40LG
  - TLR4
  - PTK2
  - KRAS
  - NRAS
  - TNFRSF1A
  - MYD88
  - TRAF6
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - TRAF2
  - TANK
  - CSNK2A1
  - CSNK2A2
  - CSNK2B
  - PDK1
  - PDPK1
  - MAP3K14
  - MAP4K4
  - MAP3K7
  - NR2C2
  - AKT1
  - AKT2
  - AKT3
  - PTEN
  - IKBKG
  - CHUK
  - IKBKB
  - IKBKE
  - TBK1
  - CUX1
  - NFKB2
  - OAS3
  - PMEL
  - SART3
  - TPX2
  - SND1
  - ASCC2
  - CDH13
  - SCYL1
  - RELB
  - RELA
  - REL
  - PSMA1
  - PSMA2
  - PSMA3
  - PSMA4
  - PSMA5
  - PSMA6
  - PSMA7
  - PSMA8
  - PSMB1
  - PSMB10
  - PSMB2
  - PSMB3
  - PSMB4
  - PSMB5
  - PSMB6
  - PSMB7
  - PSMB8
  - PSMB9
  - PSMC1
  - PSMC2
  - PSMC3
  - PSMC4
  - PSMC5
  - PSMC6
  - PSMD1
  - PSMD10
  - PSMD11
  - PSMD12
  - PSMD13
  - PSMD14
  - PSMD2
  - PSMD3
  - PSMD4
  - PSMD5
  - PSMD6
  - PSMD7
  - PSMD8
  - PSMD9
  - PSME1
  - PSME2
  - PSME3
  - PSMF1
  - SEM1
  - USP5
  - NFKB1
  - TP53
  - TP63
  - TP73
  - scb
  - Toll-4
  - Tehao
  - Toll-7
  - 18w
  - Toll-6
  - Toll-9
  - MstProx
  - Tl
  - Tollo
  - Fak
  - wgn
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - pi
  - CkIIbeta
  - CkIIbeta2
  - CkIIalpha
  - Andorra
  - Anp
  - Acam
  - Ni-K
  - msn
  - Tak1
  - Akt
  - key
  - IKKepsilon
  - IKKbeta
  - Tudor-SN
  - Pep
  - Caf1-105
  - mirr
  - p53
  - betaTub60D
  - hth
  - Cancer
  - Lung cancer
---
